Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 16/20 | 0.77 |
| ▸ | MEN1 | O00255 | 15/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.77 |
| ▸ | POLB | P06746 | 7/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | MMP13 | P45452 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
| ▸ | CASP7 | P55210 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | FGB | P02675 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2338597 | 1.00 | KMT2A (0.77) | KMT2AMEN1SMN1; SMN2POLBMAPT | |
| SCHEMBL11555123 | 0.87 | MEN1 (1.00) | KMT2AMEN1SMN1; SMN2POLBMAPT | |
| SCHEMBL11278635 | 0.87 | MEN1 (1.00) | KMT2AMEN1SMN1; SMN2POLBMAPT | |
| SCHEMBL2333243 | 0.86 | MEN1 (0.81) | KMT2AMEN1SMN1; SMN2POLBMAPT | |
| SCHEMBL15995453 | 0.86 | MEN1 (0.81) | KMT2AMEN1SMN1; SMN2POLBMAPT | |
| SCHEMBL2333246 | 0.86 | MEN1 (0.81) | KMT2AMEN1SMN1; SMN2POLBMAPT | |
| SCHEMBL8606929 | 0.84 | MEN1 (0.61) | KMT2AMEN1SMN1; SMN2POLBMAPT | |
| SCHEMBL8606927 | 0.84 | MEN1 (0.61) | KMT2AMEN1SMN1; SMN2POLBMAPT | |
| SCHEMBL17069352 | 0.84 | KMT2A (0.62) | KMT2AMEN1SMN1; SMN2POLBMAPT | |
| SCHEMBL9054686 | 0.83 | MEN1 (0.60) | KMT2AMEN1SMN1; SMN2POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465882-B1 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20060252800-A1 | Anti-leishmania agent | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2006-11-09 | — | — | US | disclosed |
| US-7115640-B2 | Heterocyclic modulators of nuclear receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1623981-A1 | ANTI-LEISHMANIA AGENT | Japan Science and Technology Corporation (JP) | 2006-02-08 | — | — | EP | disclosed |
| EP-1465882-A4 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1465882-A2 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X-Ceptor Therapeutics, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040180942-A1 | Heterocyclic modulators of nuclear receptors | X-CEPTOR THERAPEUTICS, INC. | 2004-09-16 | — | — | US | disclosed |
| US-6696473-B2 | THIAZOLIDINONE DERIVATIVES; MODULATING CHOLESTEROL METABOLISM | X-CEPTOR THERAPEUTICS, INC. | 2004-02-24 | — | — | US | disclosed |
| WO-2003060078-A9 | HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20030212111-A1 | Heterocyclic modulators of nuclear receptors | AKARNA THERAPEUTICS, LTD. (GB) | 2003-11-13 | — | — | US | disclosed |
| WO-2003060078-A2 | HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180942-A1 | Heterocyclic modulators of nuclear receptors | NR1H2, NR1H3, NR1H4 | KMT2A 2838/4885MEN1 4537/4885SMN1; SMN2 4858/4885 |
| US-20030212111-A1 | Heterocyclic modulators of nuclear receptors | NR1H2, NR1H3, NR1H4 | KMT2A 2838/4885MEN1 4537/4885SMN1; SMN2 4858/4885 |
| US-20060252800-A1 | Anti-leishmania agent | RPL17, MKI67, RPS17 | KMT2A 793/4885MEN1 3444/4885SMN1; SMN2 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.